Merck (NYSE: MRK) has elected to keep its dividend steady.
On Tuesday, the sprawling pharmaceutical company said its board of directors has declared that the Q4 common stock distribution will be $0.61 per share. This is to be paid on Oct. 7 to stockholders of record as of Sept. 15. At the most recent closing share price, the dividend yield is just under 3.1%.
The amount matches each of the company's preceding three dividends; before that, Merck had dispensed $0.55 per share. The company is a reliable payer and frequent raiser of its payout, typically upping the amount once annually, generally at the end of the year. Since March 2010, the dividend has risen steadily from $0.38 per share to the current level.
The pharmaceutical sector isn't always well-stocked hunting ground for dividends, so Merck is somewhat exceptional in this regard. Returning money in this way to shareholders seems to be a priority; the dividend is being maintained even in the wake of big changes. One of the more prominent of these was its May announcement that it was acquiring buy vaccine maker Themis Bioscience.
Themis is part of Merck's efforts to develop a coronavirus vaccine. If the company can win or place in the Great Coronavirus Vaccine Race and net even a small profit on an approved solution, it stands a chance of opening a powerful new revenue stream.
Merck's shares closed higher on Tuesday, rising by almost 1%, while the overall stock market fell slightly on the day.
10 stocks we like better than Merck & Co.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 2, 2020
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.